Veru reports Q1 EPS (26c) vs. (61c) last year

Reports cash, cash equivalents and restricted cash were $33.0M as of December 31, 2025 versus $15.8M as of September 30, 2025. “The strategy for the next generation of obesity drugs should be a combination therapy with GLP-1 receptor agonists for patients to ONLY lose fat, while preserving lean mass and physical function and increasing bone mineral density for the highest quality weight reduction,” said Mitchell Steiner,CEO of Veru (VERU). “Veru’s completed positive Phase 2b QUALITY clinical trial provided the proof of concept that enobosarm could be that next generation drug in combination with a GLP-1 RA to make the weight loss journey more selective for only fat while preserving lean mass and physical function in older patients who have obesity lessening the potential risk of loss of balance, and fractures.”